Ultrasound Measurements of Hepatic Vasculatures and Hepatic Doppler Assessment of Healthy Children

February 27, 2024 updated by: Pui Kwan Joyce Chan, Hong Kong Children's Hospital

Flow dynamics in the liver is altered in different hepatobiliary and cardiac pathologies, causing changes in hepatic vasculatures sizes and flow pattern changes which can be assessed by ultrasound (USG) study. Before one can use these measurements and observations to diagnose pathologies, a clear grasp of normality is crucial.

In the field of pediatrics, this is particularly challenging as the normal range of measurements may change with age, weight, height, gender and race of children.

Taking hepatic veno-occlusive disease as an example, current literature is conflicting regarding whether sonographic findings show consistent association with the disease. Sonographic findings therefore now have limited role in contributing to the diagnosis.

This may be related to the lack of a robust age corrected normal range of measurement for reference.

Existing literature shows that the normal portal vein diameter varies with age, weight and height and possibly gender. Literature for normal measurements of hepatic vein and hepatic artery in children is lacking.

In this study, the investigators aim to conduct a prospective, cross-section observational study to establish the normal measurements ranges of hepatic vein, hepatic artery and portal vein in healthy children in the investigators' locality.

Flow patterns, including qualitative assessment and quantitative measurements of resistive index and flow velocities will also be assessed.

These age corrected normal measurements will be very helpful in the diagnosis and follow-up of hepatobiliary and cardiac pathologies associated with alterations in dynamics of hepatic circulation.

Study Overview

Detailed Description

Trial Objectives and Purpose:

  1. To establish normal limits of diameter of hepatic vein, hepatic artery and portal vein according to age, weight, height and gender.
  2. To establish normal waveform pattern in ultrasound Doppler assessment of hepatic vein, hepatic artery and portal vein. (Qualitative analysis)
  3. To establish normal limits of flow parameters assessed by ultrasound Doppler in hepatic vein, hepatic artery and portal vein according to age, weight, height and gender.

Trial Design:

A prospective cross-section observational study.

Recruitment of study subjects:

Patients attending Hong Kong Children's Hospital for clinically indicated USG examination will be invited to participate in this study under specific inclusion and exclusion criteria.

Treatment of subjects:

Recruited subjects will proceed to the clinically indicated USG study they are referred for first. After the clinically indicated USG study is completed, additional USG & Doppler assessment of hepatic vasculatures will be performed, taking an additional 5 - 10 minutes.

All examinations will be done using a Philips EPIQ 5G ultrasound machine. Curvilinear or linear probe will be used depending on subjects' physique. Size measurements, qualitative and quantitative Doppler assessment of hepatic vein, hepatic artery and portal vein will be made and recorded.

Statistical method to be employed:

Continuous variables will be tested for normality by Shapiro-Wilk's test. Simple statistics including mean and standard deviations (+/- 2 SD) will be used to determine normal ranges for age.

Comparisons will be done by student's t-test. Relations between height, weight and gender with vessels diameter will be tested by Pearson correlation.

Linear multiple regression analysis will be utilized with vessels diameter as the dependent variable.

Number of subject to be enrolled (observation study): 300

Rationale:

Sample size = (Standard normal variate)2 X (Standard deviation)2 / Presicion2 Sample size = 1.962 X 22 / 12 Sample size = 15.37

Standard normal variate = 1.96 at 5% Type I error Standard deviation = up to 2mm (from prior study of portal vein diameter) Precision = 1mm

In view of aim of determining age corrected normal range of vessels diameter in children, a much bigger sample size will be obtained to improve accuracy.

Target to include 300 children in this study.

Age groups:

Around 30 cases for each of the following age groups:

  1. 0 - 1 years old
  2. 1 - 2 years old
  3. 2 - 4 years old
  4. 4 - 6 years old
  5. 6 - 8 years old
  6. 8 - 10 years old
  7. 10 - 12 years old
  8. 12 - 14 years old
  9. 14 - 16 years old
  10. 16- 18 years old

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Pui Kwan Joyce Chan, MBChB
  • Phone Number: +85296362929
  • Email: cpk706@ha.org.hk

Study Locations

      • Hong Kong, Hong Kong
        • Recruiting
        • Hong Kong Children's Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 18 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients attending Hong Kong Children's Hospital for clinically indicated USG examination will be invited to participate in this study.

Description

Inclusion Criteria:

  1. Patient < / = 18 years of age.
  2. No history of hepatobiliary nor cardiac pathology as checked with record in ePR. Verbal confirmation will be done with patient or parent / legal guardian.
  3. Attending USG study other than that of the hepatobiliary system. (ie. Patients attending for thyroid USG, urinary system USG, musculoskeletal system USG etc.)

Exclusion Criteria:

  1. Patient > 18 years of age
  2. Known history of hepatobiliary or cardiac pathology.
  3. Unstable patients.
  4. Intolerance of USG examination
  5. Uncooperative patients.
  6. Patient requiring sedation for USG study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hepatic veins diameter (in mm) measured by grey scale ultrasound at 1 - 2 cm from confluence with inferior vena cava
Time Frame: Baseline
Right, middle and left hepatic vein diameter (in mm) measured by grey scale Ultrasound at location 1 - 2 cm from confluence with inferior vena cava, measured in longitudinal axis
Baseline
Hepatic veins Doppler assessment of flow direction (towards or away from inferior vena cava)
Time Frame: Baseline
Ultrasound Doppler assessment of right, middle and left hepatic veins for flow direction (towards or away from inferior vena cava)
Baseline
Hepatic veins Doppler assessment of flow pulsatility (yes or no)
Time Frame: Baseline
Ultrasound Doppler assessment of right, middle and left hepatic veins for flow pulsatility (yes or no)
Baseline
Hepatic veins Doppler assessment of flow phasicity (monophasic, biphasic or triphasic)
Time Frame: Baseline
Ultrasound Doppler assessment of right, middle and left hepatic veins for flow phasicity (monophasic, biphasic or triphasic)
Baseline
Hepatic veins Quantitative Doppler measurement of maximum flow rate (cm/s)
Time Frame: Baseline
Ultrasound Doppler quantitative measurement of right, middle and left hepatic veins maximum flow rate (cm/s)
Baseline
Hepatic veins Quantitative Doppler measurement of minimum flow rate (cm/s)
Time Frame: Baseline
Ultrasound Doppler quantitative measurement of right, middle and left hepatic veins minimum flow rate (cm/s)
Baseline
Hepatic veins Quantitative Doppler measurement of pulsatility index (only if pulsatility is present)
Time Frame: Baseline
Ultrasound Doppler quantitative measurement of right, middle and left hepatic veins pulsatility index (Only if pulsatility is present)
Baseline
Hepatic artery diameter (in mm) measured by grey scale ultrasound at liver hilum
Time Frame: Baseline
Hepatic artery diameter (in mm) measured by grey scale ultrasound at the hepatic hilum (longitudinal axis)
Baseline
Hepatic artery Doppler assessment of flow direction (hepatofugal or hepatopetal)
Time Frame: Baseline
Ultrasound Doppler assessment of hepatic artery flow direction (hepatofugal or hepatopetal)
Baseline
Hepatic artery Doppler assessment of flow pulsatility (yes or no)
Time Frame: Baseline
Ultrasound Doppler assessment of hepatic artery flow pulsatility (yes or no)
Baseline
Hepatic artery Doppler assessment of flow phasicity (monophasic, biphasic or triphasic)
Time Frame: Baseline
Ultrasound Doppler assessment of hepatic artery flow phasicity (monophasic, biphasic or triphasic)
Baseline
Hepatic artery quantitative Doppler measurement of peak systolic velocity (cm/s)
Time Frame: Baseline
Ultrasound Doppler quantitative measurement of hepatic artery peak systolic velocity (cm/s)
Baseline
Hepatic artery quantitative Doppler measurement of end diastolic velocity (cm/s)
Time Frame: Baseline
Ultrasound Doppler quantitative measurement of hepatic artery end diastolic velocity (cm/s)
Baseline
Hepatic artery quantitative Doppler measurement of pulsatility index
Time Frame: Baseline
Ultrasound Doppler quantitative measurement of hepatic artery pulsatility index
Baseline
Hepatic artery quantitative Doppler measurement of resistive index
Time Frame: Baseline
Ultrasound Doppler quantitative measurement of hepatic artery resistive index
Baseline
Hepatic artery quantitative Doppler measurement of flow volume (ml/s) (measured if feasible)
Time Frame: Baseline
Ultrasound Doppler quantitative measurement of hepatic artery flow volume (ml/s)
Baseline
Portal vein diameter (in mm) measured by grey scale ultrasound at liver hilum
Time Frame: Baseline
Portal vein diameter (in mm) measured by grey scale ultrasound at liver hilum (longitudinal axis)
Baseline
Portal vein Doppler assessment of flow direction (hepatopetal or hepatofugal)
Time Frame: Baseline
Ultrasound Doppler assessment of portal vein flow direction (hepatopetal or hepatofugal)
Baseline
Portal vein Doppler assessment of flow pulsatility (yes or no)
Time Frame: Baseline
Ultrasound Doppler assessment of portal vein pulsatility (yes or no)
Baseline
Portal vein Doppler assessment of flow phasicity (monophasic, biphasic or triphasic)
Time Frame: Baseline
Ultrasound Doppler assessment of portal vein flow phasicity (monophasic, biphasic or triphasic)
Baseline
Portal vein quantitative Doppler measurement of maximum flow rate (cm/s)
Time Frame: Baseline
Ultrasound Doppler quantitative measurement of portal vein maximum flow rate (cm/s)
Baseline
Portal vein quantitative Doppler measurement of minimum flow rate (cm/s)
Time Frame: Baseline
Ultrasound Doppler measurement of portal vein minimum flow rate (cm/s)
Baseline
Portal vein quantitative Doppler measurement of pulsatility index (only if pulsatility is present)
Time Frame: Baseline
Ultrasound Doppler quantitative measurement of portal vein pulsatility index
Baseline
Portal vein quantitative Doppler measurement of flow volume (ml/s)
Time Frame: Baseline
Ultrasound Doppler measurement of portal vein flow volume (ml/s)
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pui Kwan Joyce Chan, MBChB, Hong Kong Children's Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2020

Primary Completion (Estimated)

July 31, 2024

Study Completion (Estimated)

December 31, 2024

Study Registration Dates

First Submitted

October 29, 2020

First Submitted That Met QC Criteria

November 3, 2020

First Posted (Actual)

November 6, 2020

Study Record Updates

Last Update Posted (Estimated)

February 29, 2024

Last Update Submitted That Met QC Criteria

February 27, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • HKCHUSG01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Portal Vein

3
Subscribe